Nabla Bio is building an end-to-end antibody creation platform. Nabla Bio is applying natural language processing algorithms to amino acids generating a predictive “biophysical fingerprint” for 1 million antibodies in a single step.
14 open · 3 remote · 24 filled
Nabla Bio's integrated AI and wet-lab platform accelerates antibody discovery, delivering five programs in six weeks with double-digit hit rates and partnerships with AstraZeneca, Bristol Myers Squibb, and Takeda.
Nabla Bio hiring guide: explore the company's two recruitment surfaces, salary bands for commercial and technical roles, the multi-stage interview process, in-person vs remote work locations, and what traits make candidates thrive in this fast-paced biotech.
Nabla secures $70M Series C to transition from an ambient scribe to an agentic clinical AI platform, facing intense competition from Microsoft's Nuance and Abridge.
Nabla Bio raised $70M in Series C funding and secured a $1B+ partnership with Takeda, signaling AI-driven biologics have entered core pharma R&D strategy. The company is hiring ML engineers, protein engineers, and computational biologists across Paris and the US.
